The stock of Vigil Neuroscience Inc (VIGL) has gone down by -3.11% for the week, with a 52.01% rise in the past month and a -25.91% drop in the past quarter. The volatility ratio for the week is 8.81%, and the volatility levels for the past 30 days are 11.73% for VIGL. The simple moving average for the last 20 days is 12.95% for VIGL stock, with a simple moving average of -17.92% for the last 200 days.
Is It Worth Investing in Vigil Neuroscience Inc (NASDAQ: VIGL) Right Now?
The stock has a 36-month beta value of 1.85. Opinions on the stock are mixed, with 6 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 1 as “sell.”
The public float for VIGL is 19.36M, and at present, short sellers hold a 9.37% of that float. On February 12, 2025, the average trading volume of VIGL was 1.07M shares.
VIGL) stock’s latest price update
Vigil Neuroscience Inc (NASDAQ: VIGL) has seen a decline in its stock price by -0.19 in relation to its previous close of 2.65. However, the company has experienced a -3.11% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-01-30 that WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) — Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that management will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on February 6, 2025, at 10:30 a.m. ET.
Analysts’ Opinion of VIGL
Morgan Stanley, on the other hand, stated in their research note that they expect to see VIGL reach a price target of $4, previously predicting the price at $13. The rating they have provided for VIGL stocks is “Underweight” according to the report published on December 19th, 2023.
JMP Securities gave a rating of “Mkt Outperform” to VIGL, setting the target price at $23 in the report published on October 18th of the previous year.
VIGL Trading at 26.59% from the 50-Day Moving Average
After a stumble in the market that brought VIGL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -56.35% of loss for the given period.
Volatility was left at 11.73%, however, over the last 30 days, the volatility rate increased by 8.81%, as shares surge +48.03% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +14.57% upper at present.
During the last 5 trading sessions, VIGL fell by -3.48%, which changed the moving average for the period of 200-days by +2.13% in comparison to the 20-day moving average, which settled at $2.34. In addition, Vigil Neuroscience Inc saw 55.59% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VIGL starting from Budd Haeberlein Samantha L., who purchase 12,000 shares at the price of $1.71 back on Dec 19 ’24. After this action, Budd Haeberlein Samantha L. now owns 12,000 shares of Vigil Neuroscience Inc, valued at $20,520 using the latest closing price.
Magovcevic-Liebisch Ivana, the President and CEO of Vigil Neuroscience Inc, purchase 5,000 shares at $1.68 during a trade that took place back on Dec 19 ’24, which means that Magovcevic-Liebisch Ivana is holding 222,687 shares at $8,400 based on the most recent closing price.
Stock Fundamentals for VIGL
Current profitability levels for the company are sitting at:
- -45.72 for the present operating margin
- 0.82 for the gross margin
The net margin for Vigil Neuroscience Inc stands at -42.71. The total capital return value is set at -0.88. Equity return is now at value -73.62, with -56.88 for asset returns.
Based on Vigil Neuroscience Inc (VIGL), the company’s capital structure generated 0.13 points at debt to capital in total, while cash flow to debt ratio is standing at -3.69. The debt to equity ratio resting at 0.15. The interest coverage ratio of the stock is -84.62.
Currently, EBITDA for the company is -88.47 million with net debt to EBITDA at 0.36. When we switch over and look at the enterprise to sales, we see a ratio of 39.51. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.72.
Conclusion
To sum up, Vigil Neuroscience Inc (VIGL) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
